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Abstract
Background: Complicated skin and skin structure infections (cSSSIs) are a common reason for hospitalization.
Inappropriate empiric therapy prolongs the hospital stay. Strategies that help clinicians target empiric therapy
underlie antibiotic stewardship. We developed an algorithm to identify mixed (gram-positive + gram-negative
organisms) cSSSI at hospital admission.
Methods: We performed a retrospective cohort study at a single academic medical center among patients
hospitalized from April 2006 to December 2007 with a cSSSI. Inappropriate empiric therapy was defined as
failure to deliver an antibiotic with in vitro activity against the offending pathogen(s) within 24 h of presentation.
We derived a predictive rule to identify patients at risk for a mixed skin infection (MSI) and compared it with the
‘‘healthcare-associated’’ (HCA) definition.
Results: Among 717 patients hospitalized with a cSSSI, 68 (9.5%) had an MSI, with 38.2% of these receiving
inappropriate empiric therapy. Intensive care unit admission (odds ratio [OR] 2.49; 95% confidence interval [CI]
1.12-5.52), infection other than an abscess (OR 2.01; 95% CI 1.06-3.81), and nursing home residence (OR 1.99; 95%
CI 1.05-3.78) predicted MSI independently. The absence of all three factors identified non-MSI with 95.2%
accuracy. The MSI rule improved the HCA classification accuracy for non-MSI by 21.9% without any loss in
sensitivity.
Conclusions: Hospitalization with an MSI is a risk factor for inappropriate empiric therapy. Intensive care unit
admission, infection other than an abscess, and nursing home residence help identify those patients with a
higher MSI risk. Absence of all these factors reliably identified patients not needing empiric MSI coverage.
Relative to the HCA definition, the MSI rule resulted in the potential to prevent more than one in five additional
patients from receiving unnecessarily broad empiric coverage.
Complicated skin and skin structure infections(cSSSI) are a common and growing cause of hospitali-
zation. For example, Staphylococcus aureus-related cellulitis
hospitalizations increased four-fold in a recent six-year period
and now account for 90,000 discharges annually [1]. Resistant
organisms particularly remain a burden in this syndrome,
with methicillin-resistant S. aureus (MRSA) accounting for
15% of all cases of cellulitis [2]. At the same time, gram-
negative organisms are increasingly prevalent in this condi-
tion. Antimicrobial resistance among some gram-negative
organisms is extensive [3,4]. This pattern of extensive
resistance has resulted in greater utilization of broad-
spectrum agents. Although this practice may enhance the like-
lihood a patient is treated appropriately, overuse of such agents
clearly contributes to greater rates of resistance generally.
Contributing to the prescription of broader-spectrum an-
tibiotics is the observation that use of a narrow empiric an-
timicrobial treatment prior to the identification of the
causative organism may result in the patient receiving in-
appropriate therapy initially. Inappropriate therapy can
adversely affect the mortality rate while simultaneously
prolonging hospitalization [5].
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In an effort to balance the need to ensure that a patient
receives appropriate empiric coverage with the pressure to
limit the use of broad-spectrum agents, physicians require
tools to identify persons most likely to merit broad-spectrum
therapy. Alternatively, early and accurate identification of
those patients in whom coverage may be limited can preserve
microbial susceptibility to current antibiotics. One risk-based
approach is the concept of healthcare-associated (HCA) in-
fection, which aims to have physicians treat broadly those
patients who have been hospitalized or received antimicrobial
therapy recently, who are residents of a nursing facility, or
who are on chronic hemodialysis. Unfortunately, the majority
of subjects (nearly three quarters) now admitted with cSSSI
meet the definitional requirements for an HCA, but fewer
than 50% actually are infected with resistant organisms [5].
Concurrently, however, we observed that subjects withmixed
skin infections (MSI), defined as the presence in culture of
both a gram-positive and a gram-negative organism, occur-
ring in approximately 10% of all cSSSI patients, were at high
risk for inappropriate empiric therapy. Therefore, we sought
to identify variables associated with such mixed infections to
aid physicians in more appropriate utilization of broad-
spectrum agents, confining them to situations in which they
are in fact needed.
Patients and Methods
Study design
We performed a single-center retrospective cohort study
of patients with cSSSI admitted to the hospital through
the emergency department (ED). All consecutive patients
hospitalized between April 2006 and December 2007
meeting the inclusion criteria (see below) were enrolled.
The study was approved by the Washington University
School of Medicine Human Studies Committee, and in-
formed consent was waived. This population has been
described previously [5–7].
Patients
Consecutive patients admitted from the community
through the ED between April 2006 and December 2007 at the
Barnes-Jewish Hospital, a 1,200-bed university-affiliated,
urban teaching hospital in St. Louis, MO, were included if
they had a cSSSI (Appendix 1) [8], and there was a bacterial
infection, defined as a positive culture within 24 h of hospital
admission. We excluded patients if certain diagnoses and
procedures were present (Appendix 2) [8]. Patients were also
excluded if they represented a readmission for the same
diagnosis within 30 days of the original hospitalization. All
inclusions and exclusions were based on the International
Classification of Diseases, version 9, Clinical Modification
(ICD-9-CM) coding. Notably, such deep infections as necro-
tizing fasciitis and gangrene were excluded.
Definitions
An HCA cSSSI was defined as any cSSSI in a patient with
recent hospitalization (within the previous year [6]), antibi-
otics in the 90 d prior to admission, transfer from a nursing
home, or need for dialysis. An MSI represented an infection
with both a gram-positive and a gram-negative organism.
Inappropriate empiric therapy was said to have been given if
there was a delay of ‡ 24 h in treatment with an agent ex-
hibiting in vitro activity against the pathogen(s) isolated.
Data elements
The following demographic and clinical baseline charac-
teristics were collected: Age, gender, race/ethnicity, co-
morbidities, the presence of risk factors for HCA cSSSI, the
presence of bacteremia at admission, and the location of the
admission (ward vs. intensive care unit [ICU]). Bacteriology
data included information on the specific bacterium or bac-
teria recovered, the site of the culture (e.g., tissue, blood),
antibiotic susceptibility patterns, and whether the infection
was monomicrobial, polymicrobial, or mixed. Treatment data
included information on the choice of antimicrobial therapy
and the timing of its institution relative to the obtaining of the
culture specimen. The occurrence of such procedures as inci-
sion and drainage or debridement was recorded.
Statistical analyses
We developed a risk stratification algorithm to allow
clinicians to identify at admission the patient’s risk for an MSI
in order to target empiric therapy appropriately. We first
examined descriptive comparisons between patients with and
without MSI on the basis of their clinical, demographic, mi-
crobiologic, and treatment characteristics. All continuous
variables were compared using the student t-test for para-
metric and the Mann-Whitney U test for nonparametric dis-
tributions. All categorical variables were compared using the
w2 test when the number of observations was five or greater
and the Fisher exact test when the number of observations was
fewer than five. All variables differing at a < 0.2, in addition to
those meeting the criteria for clinical plausibility, were in-
cluded in the multivariable logistic regression model to ex-
amine independent predictors of MSI. Differences were
deemed significant at a< 0.05. Model discrimination was
measured with the c-statistic and calibration with the Hosmer
Lemeshow goodness-of-fit test. Positive and negative predic-
tive values (PPVs, NPVs, respectively), of the risk factors alone
and in combination were computed. TheMSI prediction rule’s
success in detectingMSI were compared with that of the HCA
risk factors. All calculations were performed in Stata version
9.2 (Statacorp, College Station, TX).
Results
Among the 717 patients admitted to the hospital with a
cSSSI, 68 (9.5%) had an MSI, of whom 38.2% received inap-
propriate empiric therapy. The most frequent sources of cul-
ture were blood (n = 372; 51.9%), wound (n = 137; 19.1%), and
tissue (n = 57; 7.9%). At baseline, MSI patients were similar to
their non-MSI counterparts with regard to demographic fac-
tors and the prevalence of comorbidities (Table 1). Ad-
ditionally, MSIs were more likely to be classified as HCA
(82.4%) than were non-MSIs (72.6%; p= 0.085). Two specific
HCA risk factors occurred more often in the MSI cohort: Re-
cent hospitalization (80.9% in MSI vs. 66.0% in non-MSI;
p = 0.014) and nursing home residence (22.1% vs. 10.5%;
p = 0.005); (Table 1). Whereas cellulitis and abscess were more
prevalent infection types in the non-MSI group, decubitus and
diabetic foot ulcers were more frequent in the setting of MSI
(Table 1). With respect to bacteriology results, cultures from
378 ZILBERBERG ET AL.
626 patients (96.5%) with non-MSI grew out either a gram-
negative or a gram-positive organism, with 38 cultures (5.9%),
33 ofwhichwereblood cultures, yieldingCandida spp. (Table 2).
Whereas most types of organism were more prevalent in
the MSI group, such frequent culprits as S. aureus, and spe-
cifically MRSA, were balanced evenly between the two
groups (Table 2). Notably, the prevalence of gram-positive
pathogens was 74.7% in the non-MSI group, whereas that
of gram-negative organisms was 21.7%, with Pseudomonas
aeruginosa occurring in only 6.2% of all non-MSIs (Table 2).
We explored the details of the missing coverage among the
28 MSI patients receiving inappropriate empiric therapy
(Table 3). The most frequently missed gram-negative
coverage was for P. aeruginosa (n = 6; 23.1%), whereas that for
gram-positive organisms was for vancomycin-resistant en-
terococci (VRE; n = 9; 34.6%). Patients in the MSI group had a
greater severity of illness, as evidenced by their being more
than twice as likely to require ICU care than the non-MSI
group (Table 4). Along with this, they were nearly twice as
likely to receive inappropriate empiric therapy (Table 4). The
hospital mortality rate and length of stay (LOS) were direc-
tionally higher among patients with MSIs than among those
with non-MSIs, although these differences did not reach sta-
tistical significance (Table 4).
Table 1. Patient Baseline Characteristics
and Infection Types
Mixed
(n = 68)
Nonmixed
(n = 649)
p
valuea
Age 53.5 – 18.1 51.2 – 17.4 0.315
Female (%) 35 (51.5) 330 (62.2) 0.905
Race (%)
Caucasian 33 (48.5) 307 (47.3) 0.946
African American 33 (48.5) 326 (50.2)
Other 2 ( 2.9) 16 ( 2.5)
Comorbidities (%)
Diabetes mellitus 22 (32.4) 189 (29.1) 0.578
Peripheral vascular
disease
1 ( 1.5) 21 ( 3.2) 0.713
Liver disease 7 (10.3) 45 ( 6.9) 0.309
Malignant disease 15 (22.1) 99 (15.3) 0.144
Human
immunodeficicency
virus infection
1 ( 1.5) 20 ( 3.1) 0.711
Organ transplant 1 ( 1.5) 11 ( 1.7) 1.000
Autoimmune disease 2 ( 2.9) 13 ( 2.0) 0.645
End-stage renal disease 6 ( 8.8) 65 (10.0) 1.000
HCAI (%) 56 (82.4) 471 (72.6) 0.085
HCAI risk factors (%)
Hospitalization 55 (80.9) 428 (66.0) 0.014
Antibiotics 13 (19.1) 103 (15.9) 0.489
Nursing home 15 (22.1) 68 (10.5) 0.005
Dialysis 5 ( 7.4) 53 ( 8.2) 0.812
Type of infection (%)b
Cellulitis 23 (33.8) 326 (50.2) 0.010
Decubitus ulcer 16 (23.5) 71 (10.9) 0.002
Surgical site 8 (11.8) 106 (16.3) 0.327
Device-associated
infection
17 (25.0) 165 (25.4) 0.939
Diabetic foot ulcer 8 (11.8) 34 ( 5.2) 0.029
Abscess 13 (19.1) 230 (35.4) 0.007
Otherc 3 ( 4.4) 23 ( 3.5) 0.729
aP values derived using Student’s t-test for continuous variables,
w2 test for categorical variables with five or more values per cell, and
the Fisher exact test for categorical variables with five or fewer
values per cell.
bNumbers add up to more than 100% because of overlap in
diagnoses.
cOther infection types: Pilonidal cyst (n = 3); skin and subcutane-
ous structures (n = 2); chronic ulcer (n = 13); stump infection (n = 9).
HCAI=healthcare-associated infection.
Table 2. Bacteriology Findings
Mixed
(n = 68)
Nonmixed
(n = 649)
p
valuea
Gram-negative
organisms (%)
68 (100) 141 (21.7) < 0.001
Acinetobacter 6 ( 8.8) 6 ( 0.9) < 0.001
Citrobacter 4 ( 5.8) 8 ( 1.2) 0.020
Enterobacter 9 ( 13.2) 14 ( 2.2) < 0.001
Escherichia coli 12 ( 17.6) 35 ( 5.4) 0.001
Klebsiella 10 ( 14.7) 26 ( 4.0) 0.001
Morganella 3 ( 4.4) 3 ( 0.5) 0.013
Proteus 6 ( 8.8) 15 ( 2.3) 0.010
Pseudomonas 21 ( 30.9) 40 ( 6.2) < 0.001
Serratia 1 ( 1.5) 9 ( 1.4) 1.000
Stenotrophomonas 1 ( 1.5) 5 ( 0.8) 0.451
Bacteroides 6 ( 8.8) 13 ( 2.0) 0.006
Gram-positive
organisms (%)
68 (100) 485 (74.7) < 0.001
VRE 10 ( 14.7) 18 ( 2.8) < 0.001
Enterococcus faecalis 14 ( 20.6) 37 ( 5.7) < 0.001
Enterococcus faecium 7 ( 10.3) 20 ( 3.1) 0.010
Staphylococcus aureus 37 ( 54.4) 346 (53.3) 0.899
MRSA 23 ( 33.8) 229 (35.3) 0.894
MSSA 14 ( 20.6) 119 (18.3) 0.625
Streptococcus spp. 6 ( 8.8) 40 ( 6.2) 0.430
Candida spp. (%) 6 ( 8.8) 38 ( 5.9) 0.019
aP values derived using Fisher exact test for categorical variables.
VRE =vancomycin-resistant Enterococcus; MRSA =methicillin-
resistant Staphylococcus aureus; MSSA=methicillin-sensitive S. aureus.
Table 3. Type of Missing Empiric Coverage
among Patients with Mixed Complicated Skin
and Skin Structure Infections Receiving
Inappropriate Empiric Therapy (n = 26)
Organism type No. (%)
Any gram-negative organism, including
Psuedomonas aeruginosa
18 (69.2)
P. aeruginosa 6 (23.1)
Gram-negative and not gram-positive 11 (42.3)
P. aeruginosa and not gram-positive 4 (15.4)
Any gram-positive organism
(including MRSA and VRE)
15 (57.7)
MRSA 3 (11.5)
VRE 9 (34.6)
Gram-positive and not gram-negative 8 (30.8)
MRSA and not gram-negative 2 ( 7.7)
VRE and not gram-negative 6 (23.1)
Gram-negative and gram-positive 7 (26.9)
MRSA=methicillin-resistantStaphylococcus aureus; VRE=vancomycin-
resistant Enterococcus.
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In a logistic regression with MSI as the dependent variable,
three factors emerged as significantly associated with the risk
of an MSI: Need for ICU admission, infection that was not an
abscess, and previous residence in a nursing home (Table 5).
Although the calibration of themodel was adequate (Hosmer-
Lemeshow goodness-of-fit p = 0.931), the discrimination was
only fair (c statistic 0.63). As a screening test for the presence of
an MSI, the PPV of having at least one of the identified risk
factors was poor (11.66%). Alternatively, the NPV exceeded
95% (Table 5). Although increasing the number of risk factors
improved the PPV for MSI slightly, it also resulted in a re-
duction in the NPV (data not shown).
The comparison of MSI algorithm’s characteristics with the
HCA risk factors at identifying or excluding the presence of
MSI showed no differences in either calibration, along with
slightly better discrimination for theMSI risk factors (Table 6).
However, although the absence of HCA risk factors would
disqualify 178 of 190 patients correctly from dual coverage
against both gram-positive and gram-negative organisms, the
MSI algorithm would exclude 217 of 228, resulting in an in-
crease in classification accuracy of 20.5% of non-MSI without
any loss in the sensitivity for MSI (Table 6).
Discussion
We demonstrate that in a broad cohort of patients admitted
to a large urban academicmedical center from the community
and having a cSSSI, approximately 10% had an MSI.
Compared with non-MSIs, patients with MSIs were more
likely to be classified as having an HCA cSSSI and to receive
inappropriate empiric therapy. Because the presence of an
MSI is associated with inappropriate empiric therapy, it
presents a potential novel target for early recognition to tailor
appropriate therapy. To aid clinicians in this task, we devel-
oped a simple bedside decision rule, by which if, at hospi-
talization, the patient does not require ICU care, his or her
infection is an abscess, and he or she is not a nursing home
resident, the likelihood that the infection is not anMSI exceeds
95%. This rule may help physicians identify subjects who do
not require drugs to cover both a gram-negative and a gram-
positive organism. Whereas the absence of HCA risk factors
also results in a nearly 95% exclusion of MSI, the absolute
number ofmisclassifications favors using ourMSI risk factors.
Namely, the greater specificity and NPV of the MSI rules
compared with the HCA definition could help shield an ad-
ditional 20.5% of patients from unnecessarily broad-spectrum
treatment without any loss in sensitivity for MSI.
Combating further emergence of antimicrobial resistance
requires a thoughtful approach to choosing empiric therapy.
At the same time, strong data indicate that inadequate cov-
erage early in the course of the infection markedly worsens
outcomes. For example, the mortality rates in pneumonia [9–
14] and blood stream [15–22] and other [23] infections are
elevated when inadequate empiric coverage is chosen, a rise
that is not attenuated by antibiotic escalation in response to
culture results [24]. To improve early decision making, the
concept of HCA infection was developed. The idea was to
bring into sharper relief the risk factors predisposing patients
coming in from the community to infections with pathogens
traditionally found to be responsible for nosocomial infec-
tions. Although these definitions have been incorporated into
evidence-based practice guidelines [25], they have never been
validated. Furthermore, emerging evidence suggests that the
HCA definition’s lack of specificity results in more permissive
use of broad-spectrum antibiotics, thus heightening concerns
about selective pressure to promote further resistance and
even to worsen individual patient outcomes [26].
In the case of cSSSI, although inappropriate empiric ther-
apy does not appear to elevate the risk of in-hospital death, it
does alter hospital resource utilization [6]. In the same data set
analyzed in the current study, in a generalized linear model
with the log-transformed LOS as the dependent variable,
adjusting for multiple potential confounders, inappropriate
empiric therapy conferred an attributable incremental in-
crease in the hospital LOS of 1.8 days (95% CI 1.4-2.3) [6].
Together with the concerns about resistance pressures stem-
ming from unnecessarily broad empiric coverage, the concern
about the most efficient use of healthcare resources is a com-
pelling impetus for developing risk stratification algorithms
to use at the bedside, which can help clinicians develop ap-
propriate coverage decisions that align with the goals of both
best clinical care and antibiotic stewardship. Our identifica-
tion of MSI as a risk group for inappropriate empiric therapy
and the development of a simple decision rule to limit the
probability of an MSI is consonant with this philosophy.
There is a bewildering lack of mention of the probability of
a cSSSI being caused by both a gram-positive and a gram-
negative organism in the most recent evidence-based practice
guidelines from the Infectious Diseases Society of America
[27]. Their guideline committee focused mostly on such
Table 4. Processes of Care and Outcomes
Mixed
(n = 68)
Nonmixed
(n = 649)
p
valuea
Inappropriate
treatment (%)
26 (38.2) 132 (20.3) 0.002
ICU admission (%) 9 (13.2) 33 ( 5.1) 0.013
Debridement (%) 19 (27.9) 256 (39.5) 0.063
Hospital mortality
rate (%)
6 ( 8.8) 31 ( 4.8) 0.151
Hospital LOS, days
Mean (SD) 9.7 (13.5) 8.2 (12.7)
Median (IQR) 6.2 (3.6, 10.7) 5 (2.6, 9.7) 0.065
aMann-Whitney U test.
ICU= intensive care unit; LOS= length of stay; SD= standard
deviation; IQR= interquartile range.
Table 5. Predictors of Mixed Infection
Present on Admissiona
Risk factor Odds ratio 95% CI P valueb
ICU admission 2.49 1.12-5.52 0.025
Infection type: Not abscess 2.01 1.06-3.81 0.032
Nursing home 1.99 1.05-3.78 0.036
aFactors entered in regression (at univariable a < 0.2) but not
retained at p < 0.05 were recent hospitalization, cancer, cellulitis,
decubitus ulcer, diabetic foot infection; factors not entered because of
co-linearity were healthcare-associated infection (colinear with recent
hospitalization and nursing home residence) and diabetes mellitus
(co-linear with diabetic foot infection).
bCalibration: Hosmer-Lemeshow goodness-of-fit w2 p = 0.931;
discrimination: c-statistic = 0.63.
CI= confidence interval; ICU= intensive care unit.
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gram-positive pathogens as S. aureus and S. pyogenes. Al-
though acknowledging resistance emergence in both, little
attention is afforded to gram-negative culprits, either singly or
in combination with gram-positive bacteria. The fact that our
study, conducted subsequent to the publication of the above
guideline in 2005, has discovered a 10% prevalence of MSI
among patients hospitalized with cSSSI likely attests to the
continuing shifts in the bacteriology of infectious disease in
general and cSSSI in particular. However, given the single-
center nature of our study, the data require confirmation in a
larger, preferably multicenter, study.
Along these lines, our data suggest that the risk of having a
gram-negative cSSSI in the setting of a non-MSI is substan-
tially lower (21.7%) than that of a gram-positive infection
(74.7%). The fact that roughly one in five patients withoutMSI
risk factors may still be infected with a gram-negative path-
ogen is worrisome and suggests that additional risk stratifi-
cation algorithms to identify these patients early are required
to tailor appropriate coverage. However, it is helpful to rec-
ognize that P. aeruginosa is indeed a rare culprit in non-MSI,
and this can have immediate implications for narrowing
empiric coverage away from antipseudomonal agents. It is
important to note that in our data, the prevalence of gram-
negative infection is higher than in a recently reported cohort
from another academic medical center [28], implying that
local bacteriology patterns should remain the primary drivers
of empiric treatment decisions.
Our study has a number of limitations. First, as a retro-
spective cohort study, it is prone to various forms of bias, most
notably selection bias. To minimize the possibility of such, we
established a priori case definitions and enrolled consecutive
patients over a specific period of time. Second, as in any ob-
servational study, confounding is an issue. Although we de-
veloped regression models to account for factors that impact
the risk of MSI, residual confounding remains a concern.
Third, we identified only a small number of MSIs, and this
necessarily limited our ability to validate the predictive
model. Validation in a large multicenter cohort is necessary to
improve the generalizability of our results.
In summary, an MSI is present in 10% of all patients
admitted from the community with a cSSSI. These patients
are more likely than those without an MSI to receive ini-
tially inappropriate empiric antibiotic therapy. To balance
the benefit of tailored appropriately broad coverage for
these patients with the concerns about promoting antimi-
crobial resistance, our simple bedside rule can identify with
95% reliability those patients who are at low risk for an
MSI, and thus limit the use of broad-spectrum antimicrobial
drugs.
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Appendix 1. Inclusion Criteria According
to International Classification of Diseases,
Ninth Revision, Clinical Modification
(ICD-9-CM) Code
Principal
diagnosis code Description
680 Carbuncle and furuncle
681 Cellulitis and abscess of finger and toe
682 Other cellulitis and abscess
683 Acute lymphadenitis
685 Pilonidal cyst with abscess
686 Other local infections of skin and
subcutaneous tissue
707 Decubitus ulcer
707.1 Ulcers of lower limbs, except
decubitus ulcer
707.8 Chronic ulcer of other specified sites
707.9 Chronic ulcer of unspecified site
958.3 Posttraumatic wound infection,
not elsewhere classified
996.62 Infection attributable to other vascular
device, implant, and graft
997.62 Infection (chronic) of amputation stump
998.5 Postoperative wound infection
Appendix 2. Excluded ICD-9-CM Codes
Diagnosis code Description
728.86 Necrotizing fasciitis
785.4 Gangrene
686.09 Erethyma gangrenosum
730.00–730.2 Osteomyelitis
630–677 Complications of pregnancy, childbirth,
and puerperium
288.0 Neutropenia
684 Impetigo
Procedure code
39.95 Plasmapheresis
99.71 Hemoperfusion
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